– Crizotinib in pretreatred metastatic non-small-cell lung cancer with MET amplification or ROS1 translocation (METROS)
– Analysis of circulating biomarkers in patients treated with checkpoint inhibitors
– Role of MYC amplification in response to anti-EGFR agents in NSCLC
– Role of MYC amplification in response to anti-EGFR agents in colorectal cancer
– Efficacy of Dacomitinib and PF05212384 in non-small-cell lung cancer cell lines harboring HER2 mutation
– MIR128 and LET-7 expression and efficacy of anti-EGFR therapies in metastatic NSCLC with EGFR or KRAS mutations con supporto aggiuntivo dell’Istituto Toscano Tumori
– Identification of prognostic factors in surgically resected NSCLC